Walker Neal
Known title: President and CEOCIK: 0001604457
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Biotech Sector News Dominates; No Specific ALDX Updates. Recent news coverage focuses on clinical trial results for other biotechnology companies, such as ACAD and Vertex, rather than Aldeyra Therapeutics. There are no new company-specific announcements or trial updates for ALDX in the provided reports. The stock is currently trading near its 52-week low, reflecting broader sector sentiment rather than isolated corporate news.
Transaction History
| ACRS | ▲ Buy | Option Exercise | 63,475 | — | 2/3/2026 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 18,611 | $65K | 2/3/2026 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 29,150 | — | 1/2/2026 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 9,952 | $29K | 1/2/2026 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 2,975 | $4K | 5/1/2025 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 9,467 | — | 5/1/2025 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 9,467 | — | 4/1/2025 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 3,042 | $5K | 4/1/2025 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 9,466 | — | 3/1/2025 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 3,277 | $7K | 3/1/2025 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 3,559 | $9K | 2/1/2025 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 9,467 | — | 2/1/2025 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 29,149 | — | 1/2/2025 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 13,532 | $34K | 1/2/2025 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 9,467 | — | 1/1/2025 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 3,904 | $10K | 1/1/2025 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 118,840 | $181K | 12/4/2024 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 68,343 | $257K | 12/4/2024 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 2,721 | $11K | 12/1/2024 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 9,466 | — | 12/1/2024 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 9,467 | — | 11/1/2024 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 2,721 | $6K | 11/1/2024 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 2,722 | $3K | 10/1/2024 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 9,467 | — | 10/1/2024 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 9,466 | — | 9/1/2024 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 2,722 | $3K | 9/1/2024 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 43,548 | $31K | 8/9/2024 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 9,467 | — | 8/1/2024 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 2,722 | $4K | 8/1/2024 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 9,467 | — | 7/1/2024 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 2,722 | $3K | 7/1/2024 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 2,722 | $3K | 6/1/2024 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 9,466 | — | 6/1/2024 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 9,467 | — | 5/1/2024 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 2,784 | $4K | 5/1/2024 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 9,467 | — | 4/1/2024 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 3,224 | $4K | 4/1/2024 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 9,466 | — | 3/1/2024 | View on chart |
| ACRS | ▼ Sell | Tax Withholding | 3,223 | $4K | 3/1/2024 | View on chart |
| ALDX | ▲ Buy | Option Exercise | 9,604 | $5K | 8/22/2023 | View on chart |
| ACRS | ▼ Sell | Open Market | 30,240 | $382K | 3/3/2023 | View on chart |
| ACRS | ▼ Sell | Open Market | 29,000 | $359K | 3/2/2023 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 18,254 | — | 3/2/2023 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 24,000 | — | 3/1/2023 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 96,150 | — | 3/1/2023 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 18,275 | — | 3/1/2023 | View on chart |
| ACRS | ▼ Sell | Open Market | 1,079 | $16K | 2/2/2023 | View on chart |
| ACRS | ▼ Sell | Open Market | 3,121 | $53K | 2/2/2023 | View on chart |
| ACRS | ▼ Sell | Open Market | 200 | $4K | 2/2/2023 | View on chart |
| ACRS | ▼ Sell | Open Market | 600 | $9K | 2/2/2023 | View on chart |
| ACRS | ▼ Sell | Open Market | 25,000 | $419K | 2/1/2023 | View on chart |
| ACRS | ▼ Sell | Open Market | 15,000 | $223K | 1/4/2023 | View on chart |
| ACRS | ▼ Sell | Open Market | 23,382 | $355K | 1/3/2023 | View on chart |
| ACRS | ▼ Sell | Open Market | 1,618 | $26K | 1/3/2023 | View on chart |
| ACRS | ▼ Sell | Open Market | 20,000 | $304K | 4/25/2022 | View on chart |
| ACRS | ▼ Sell | Open Market | 25,000 | $376K | 4/22/2022 | View on chart |
| ACRS | ▼ Sell | Open Market | 25,000 | $381K | 4/21/2022 | View on chart |
| ACRS | ▼ Sell | Open Market | 56,303 | $896K | 3/11/2022 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 18,254 | — | 3/2/2022 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 96,150 | — | 3/1/2022 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 18,275 | — | 3/1/2022 | View on chart |
| ACRS | ▼ Sell | Open Market | 3,595 | $46K | 2/9/2022 | View on chart |
| ACRS | ▲ Buy | Option Exercise | 10,800 | — | 2/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
ACRS Not Highlighted in Recent Pre‑Market Moves
In the past week, pre‑market activity focused on large financial names and a list of 20 stocks, but Aclaris Therapeutics was not mentioned. The moves in big banks and other sectors could influence overall market sentiment, which may affect smaller biotech names like ACRS. No direct company news was reported, so the impact is limited at this time.
ACRS Not Highlighted in Recent Pre‑Market Moves. In the past week, pre‑market activity focused on large financial names and a list of 20 stocks, but Aclaris Therapeutics was not mentioned. The moves in big banks and other sectors could influence overall market sentiment, which may affect smaller biotech names like ACRS. No direct company news was reported, so the impact is limited at this time.